Pointe foot is one of the most common clinical manifestations of cerebral palsy, caused by spasticity of the triceps muscle of the calf, in mild cases, walking instability, postural incoordination, and in severe cases, it is difficult to walk; for the treatment of spasticity, the current domestic and international treatment efficacy is not satisfactory, so successful treatment of muscle spasticity is still a difficult problem facing the medical community at present.Botulinum toxin type A (BTX-A) is a potent muscle relaxant that can relieve muscle spasms. In 1992, BTX-A began to be used in the clinical treatment of cerebral palsy. BTX-A is a protein produced by Clostridium botulinum anaerobicum, which is neurophilic and can inhibit the release of acetylcholine (Ach), leading to flaccid paralysis of muscles.After the administration of BTX-A by intramuscular injection, the excitability of the target muscle to random motor excitation and electrical nerve stimulation is reduced. After BTX-A is administered intramuscularly, the excitability of the target muscle to random motor excitation and electrical nerve stimulation is reduced. However, this change does not cause pathological changes such as degeneration, necrosis and fibrosis of muscle fibers in the true sense of the word. After a single intramuscular injection, the casual movement and muscle tone of the target muscle mostly recover after 3-6 months. So the greatest value of BTXCA injections is that they provide a therapeutic window of about six months or so. It creates favorable conditions for rehabilitation training in terms of muscle relaxation and decreased muscle tone, relaxes the spastic active muscles, and facilitates the strengthening of functional training for antagonistic muscles, thus improving the range of joint movement, enhancing motor function and improving postural abnormalities. Vital signs after BTX-A injection were stable and no systemic or systemic side effects occurred. The most common adverse reaction was pain at the injection site (98%), which was not only related to local soft tissue injury, but also to the large volume and high concentration of the injected drug solution. Therefore, syringe movement should be minimized to protect the soft tissues, and the side effects will be relatively reduced by applying an appropriate small volume and high concentration of drug solution. The second is transient muscle weakness (82%), most of them recovered in about 1 week; the most serious adverse reaction is anaphylactic shock, detailed medical history should be asked before injection, and those with hypersensitive body should avoid application.